The ACC is dedicated to creating a strong, diverse and inclusive field of future cardiovascular physicians, scientists and professionals. The ACC's Internal Medicine Cardiology and Pediatric Residents ...

With the mandatory Ambulatory Specialty Model (ASM) for Heart Failure (HF) slated to begin Jan. 1, 2027, the ACC is prioritizing member awareness and education, while pressing the Centers for Medicare ...

The Board of Governors (BOG) is the College's grassroots forum. Governors are the only elected leaders in the College, and they represent their members in Canada, Mexico, the United States and Puerto ...

The App allows you to search for ACC members by name, city, state or clinical focus. You can also update your own profile and view the latest ACC news right from the ...

Media registration information for ACC.27/WCC, taking place April 10-12, 2027, in Houston will be available in the fall of 2026.

The Electrophysiology (EP) Section is a vibrant community for all ACC members who are interested in the evaluation and management of heart rhythm disorders. The role of the EP Leadership Council is to ...

Set against the backdrop of Ponte Vedra Beach in Florida, MedAxiom CV Transforum Spring '26 brought together cardiovascular leaders in a setting that made it easy to step back, think strategically, ...

The new 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome is the first ever to address the "interrelated ...

A network meta-analysis of the discontinuation of blood-pressure (BP)-lowering medications due to adverse drug effects (AEs) found that the best-tolerated treatment was a combination of an angiotensin ...

Semaglutide improved kidney and survival outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), including those with established atherosclerotic cardiovascular disease ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators ...

Results from two early studies published in NEJM could have important implications for patients with heart failure (HF) and reduced LVEF and for adults with heterozygous familial hypercholesterolemia ...